0345: Thirty-day outcomes of transcatheter aortic valve implantation with the latest generation Edwards SAPIEN 3 prosthesis via the transiliofemoral approach

BackgroundFew data is available concerning the latest generation Edwards SAPIEN 3- S3 in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI).AimsTo evaluate periprocedural and 30-day clinical outcomes of TAVI using the Edwards SAPIEN 3 prosthesis) via transiliofemoral approach.MethodsBetween September 2014 and March 2015, consecutive high-risk or non-operable patients with severe aortic stenosis had TAVI using Edwards SAPIEN 3 prosthesis in Institut Mutualiste Montsouris. Valve Academic Research Consortium endpoints were used.ResultsOf 142 patients who underwent TAVI using Edwards SAPIEN prosthesis, 66 were treated with SAPIEN 3 via transfemoral access (mean age 84±7.1 years; 70% female). About 65% and 48% of patients had, respectively, severe peripheral artery diseases and calcified iliofemorale arteries. Multi-detector computed tomography estimated an aortic annular diameter of 25,07±2mm. Mean logistic EuroSCORE was 15,8±10,8. The device success rate was 98.5%. No failure of valve deployment had occurred and no patient had more than mild paravalvular aortic regurgitation. Mean transaortic gradient decreased from 46, 0±12,33mmHg to 8,2±3,37mmHg (p